关注
Dmitry Shcheblyakov
Dmitry Shcheblyakov
Gamaleya research institute
没有经过验证的电子邮件地址
标题
引用次数
引用次数
年份
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ...
The Lancet 397 (10275), 671-681, 2021
20472021
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
DY Logunov, IV Dolzhikova, OV Zubkova, AI Tukhvatulin, ...
The Lancet 396 (10255), 887-897, 2020
12632020
Safety and immunogenicity of GamEvac-Combi, a heterologous VSV-and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia
IV Dolzhikova, OV Zubkova, AI Tukhvatulin, AS Dzharullaeva, ...
Human vaccines & immunotherapeutics 13 (3), 613-620, 2017
1362017
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist
LG Burdelya, CM Brackett, B Kojouharov, II Gitlin, KI Leonova, ...
Proceedings of the National Academy of Sciences 110 (20), E1857-E1866, 2013
1342013
Neutralizing activity of sera from Sputnik V-vaccinated people against variants of concern (VOC: B. 1.1. 7, B. 1.351, P. 1, B. 1.617. 2, B. 1.617. 3) and Moscow endemic SARS …
VA Gushchin, IV Dolzhikova, AM Shchetinin, AS Odintsova, AE Siniavin, ...
Vaccines 9 (7), 779, 2021
1282021
Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation
DY Logunov, DV Scheblyakov, OV Zubkova, MM Shmarov, ...
Oncogene 27 (33), 4521-4531, 2008
1012008
Toll-like receptors (TLRs): the role in tumor progression
DV Shchebliakov, DY Logunov, AI Tukhvatulin, MM Shmarov, ...
Acta Naturae (англоязычная версия) 2 (3 (6)), 21-29, 2010
982010
Gam-COVID-Vac Vaccine Trial Group Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised …
DY Logunov, IV Dolzhikova, DV Shcheblyakov, AI Tukhvatulin, ...
Lancet 397 (10275), 671-681, 2021
882021
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in …
AI Tukhvatulin, IV Dolzhikova, DV Shcheblyakov, OV Zubkova, ...
The Lancet Regional Health–Europe 11, 2021
652021
Non-thermal plasma causes p53-dependent apoptosis in human colon carcinoma cells
AI Tuhvatulin, EV Sysolyatina, DV Scheblyakov, DY Logunov, ...
Acta Naturae (англоязычная версия) 4 (3 (14)), 82-87, 2012
592012
Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella …
AI Tukhvatulin, II Gitlin, DV Shcheblyakov, NM Artemicheva, LG Burdelya, ...
Infection and immunity 81 (10), 3855-3864, 2013
582013
Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice
GAL Godakova SA, Noskov AN, Vinogradova ID, Ugriumova GA, Solovyev AI ...
Toxins (Basel) 11, 2019
572019
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer
A Ghochikyan, A Pichugin, A Bagaev, A Davtyan, A Hovakimyan, ...
Journal of Translational Medicine 12, 1-12, 2014
562014
Powerful complex immunoadjuvant based on synergistic effect of combined TLR4 and NOD2 activation significantly enhances magnitude of humoral and cellular adaptive immune responses
AI Tukhvatulin, AS Dzharullaeva, NM Tukhvatulina, DV Shcheblyakov, ...
PLoS One 11 (5), e0155650, 2016
502016
Topical bacterial lipopolysaccharide application affects inflammatory response and promotes wound healing
AV Kostarnoy, PG Gancheva, DY Logunov, LV Verkhovskaya, MA Bobrov, ...
Journal of Interferon & Cytokine Research 33 (9), 514-522, 2013
432013
Virus-vectored Ebola vaccines
IV Dolzhikova, EA Tokarskaya, AS Dzharullaeva, AI Tukhvatulin, ...
Acta Naturae (англоязычная версия) 9 (3 (33)), 4-11, 2017
322017
Safety and efficacy of the Russian COVID-19 vaccine: more information needed–Authors’ reply
DY Logunov, IV Dolzhikova, AI Tukhvatullin, DV Shcheblyakov
The Lancet 396 (10256), e54-e55, 2020
282020
Retention of neutralizing response against SARS-CoV-2 omicron variant in sputnik V-Vaccinated individuals
D Lapa, DM Grousova, G Matusali, S Meschi, F Colavita, A Bettini, ...
Vaccines 10 (5), 817, 2022
262022
Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern
IA Favorskaya, DV Shcheblyakov, IB Esmagambetov, IV Dolzhikova, ...
Frontiers in immunology 13, 822159, 2022
232022
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B. 1.1. 529 (Omicron) SARS-CoV-2 variant
IV Dolzhikova, AA Iliukhina, AV Kovyrshina, AV Kuzina, VA Gushchin, ...
medRxiv, 2021.12. 17.21267976, 2021
232021
系统目前无法执行此操作,请稍后再试。
文章 1–20